Skip to main content
main-content

Tipp

Weitere Artikel dieser Ausgabe durch Wischen aufrufen

07.01.2020 | original article | Ausgabe 1-2/2020 Open Access

Wiener klinische Wochenschrift 1-2/2020

Serum levels of sclerostin reflect altered bone microarchitecture in patients with hepatic cirrhosis

Zeitschrift:
Wiener klinische Wochenschrift > Ausgabe 1-2/2020
Autoren:
M.D. Robert Wakolbinger, M.D. Associate Professor Christian Muschitz, Ph.D. Jacqueline Wallwitz, M.D. Associate Professor Gerd Bodlaj, M.D., Ph.D. Xaver Feichtinger, M.D. Jakob E. Schanda, M.D. Professor Heinrich Resch, Ph.D. Andreas Baierl, M.D. Professor Peter Pietschmann
Wichtige Hinweise

Authors contribution

Conception and design: RW, CM, GB, XF, JES, HR, AB, PP. Data acquisition, analysis and interpretation: RW, CM, JW, AB, PP. Article writing and/or critical revision of the manuscript: RW, CM, JW, GB, XF, JES, HR, AB, PP

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Summary

Background

Patients with hepatic cirrhosis are at increased risk of bone loss. Recent work on areal bone mineral density has reported contradictory findings. As the assessment of bone microarchitecture is complex, a search was made for correlations with new serum markers of bone turnover. Current data on serum sclerostin levels in patients with increased fracture risk are divergent and to date only one study has examined patients with hepatic cirrhosis. Therefore, the aim of this study was to evaluate serum sclerostin levels and to test for correlations with microarchitecture.

Methods

This study was performed in 32 patients with recently diagnosed hepatic cirrhosis and 32 controls. The parameters of bone microarchitecture were assessed by high-resolution peripheral quantitative computed tomography. Sclerostin was detected via a new ELISA that detects the active receptor interaction site at loop 2 of the sclerostin core region.

Results

Sclerostin levels were slightly, but not significantly lower in the patient group, compared to controls. In contrast, patients with alcoholic liver cirrhosis had significantly lower levels than the controls. A significant correlation with areal bone mineral density (BMD) and trabecular microarchitecture was observed in the patient group. However, there was hardly any correlation between sclerostin and bone microarchitecture in the controls.

Conclusion

In hepatic cirrhosis, sclerostin is related to altered bone microarchitecture and lower areal BMD. In alcoholic liver disease, low sclerostin concentrations were seen.

Unsere Produktempfehlungen

Abo für kostenpflichtige Inhalte

Literatur
Über diesen Artikel

Weitere Artikel der Ausgabe 1-2/2020

Wiener klinische Wochenschrift 1-2/2020 Zur Ausgabe

mitteilungen der gesellschaft

mitteilungen der gesellschaft

mitteilungen der gesellschaft der ärzte in wien

Veranstaltungstipps: